Be on Top of the latest Happenings: Complementary Research on Threshold Pharmaceuticals, Tokai Pharmaceuticals, DepoMed, Nexvet Biopharma and Pall Corporation

May 15, 2015, 08:00 ET from Analysts Review

NEW YORK, May 15, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.  

Moments ago, Analysts Review released new research updates concerning several important developing situations including Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Tokai Pharmaceuticals, Inc. (NASDAQ: TKAI), DepoMed Inc. (NASDAQ: DEPO), Nexvet Biopharma Public Limited Company (NASDAQ: NVET), and Pall Corporation (NYSE: PLL). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.

To access our full PDF reports on a complementary basis, please visit the links below.

--

Today's update concerns the following companies:

============

Full PDF Download Links (you may have to copy and paste the following links into your browser):

THLD Research Report: ( http://get.analystsreview.com/pdf/?c=Threshold%20Pharmaceuticals%20Inc.&d=15-May-2015&s=THLD ),

TKAI Research Report: ( http://get.analystsreview.com/pdf/?c=Tokai%20Pharmaceuticals%20Inc.&d=15-May-2015&s=TKAI ),

DEPO Research Report: ( http://get.analystsreview.com/pdf/?c=DepoMed%20Inc.&d=15-May-2015&s=DEPO ),

NVET Research Report: ( http://get.analystsreview.com/pdf/?c=Nexvet%20Biopharma&d=15-May-2015&s=NVET ),

PLL Research Report: ( http://get.analystsreview.com/pdf/?c=Pall%20Corporation&d=15-May-2015&s=PLL ).

============

--

Analyst Update: Earnings, Clinical Trials, Management Changes, and  Acquisitions

U.S. stocks closed higher on Thursday, recovering from a sequence of slight losses over the week. The rally came despite unexpected drop in both weekly jobless claims and headline inflation figure. The NASDAQ Composite closed at 5,050.79, up 1.39%, the S&P 500 jumped 1.08%, to 2,121.10, and the Dow Jones Industrial Average ended the session 1.06% higher, at 18,252.24. European stocks surged sharply higher on Thursday after the European Central Bank's president reaffirmed its commitment to continue massive stimulus program for the Eurozone. Germany's DAX 30 advanced 1.84%, France's CAC 40 gained 1.36%, and London's FTSE 100 closed 0.34% higher on Thursday. Meanwhile, Asian markets were once again mixed on Thursday. The Shanghai Composite and Hong Kong's Hang Seng posted modest gains, while Japan's Nikkei fell on Thursday.

Threshold Pharmaceuticals Inc. (Threshold) on May 12, 2015 announced that the Company's partner Merck KGaA, working together with Threshold on the development of evofosfamide (previously known as TH-302), an investigational compound currently in Phase 3 clinical trials, has received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development of the drug.

Tokai Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company on May 12, 2015 announced its first quarter financial results ended March 31, 2015. The Company reported a loss of $13.3 million $0.59 per share for the quarter, compared to a loss of 4.8 million or $9.79 per share.

DepoMed Inc. (DepoMed) on May 11, 2015 announced its first quarter financial results for the quarter ended March 2015, with revenues of $32.2 million. Revenue was down 57.9% compared to the first quarter of 2014 revenues of $76.5 million.

Nexvet Biopharma Public Limited Company (Nexvet) on May 11, 2015 announced that it has appointed former Elanco and Novartis Animal Health executive Dr. Jürgen Horn as its new Chief Product Development Officer. He will assume his role in August 2015.

Pall Corporation (PLL) ended on May 12, 2015 at $118.62, trading up 19.4%. A day earlier Wall Street Journal had reported that the filtration system manufacturer is in advanced stages of an auction that could push the Company's value north of $10 billion.

--

About Analysts Review  

At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.

--

Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.

Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider, represented by a registered analyst has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review